Standigm is a leading AI drug discovery company that specializes in customized novel target identification, first-in-class lead compound generation, and asset catalog creation. With a focus on innovation and efficiency, Standigm offers advanced technologies like Standigm ASK TM and Standigm BEST TM to rapidly develop unique drug compounds tailored to specific diseases. Their automated AI-driven drug discovery system ensures a regular supply of validated hit compounds, creating a never-dry asset reservoir to strengthen drug pipelines.

Standigm's proven workflow AI platform accelerates the drug discovery process, delivering first-in-class compounds within an average of 7 months. Trusted globally by partners for their exceptional results, Standigm continues to revolutionize the pharmaceutical industry with their cutting-edge solutions. Stay informed with their latest news and join the future of drug discovery with Standigm